Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model

• Status: Unknown status
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Background and Aims: The prevalence of hepatitis C virus infection (HCV) infection in Punjab, India is 3.29%, with an estimated burden of around 650,000 viremic chronic HCV (CHC) patients. The Mukh Mantri Punjab Hepatitis C Relief Fund (MMPHCRF) was launched in June 2016 to provide free treatment to all CHC aiming to eliminate HCV from Punjab. The study assessed the feasibility of decentralized care and efficacy and safety of 12 or 24 weeks of sofosbuvir (SOF) + ledipasvir (LDV) or SOF + daclatasvir (DCV) ± ribavirin (RBV) in the treatment of CHC patients in a public health care setting.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Postgraduate Institute of Medical Education and Research
• Collaborator: Directorate of Health and Family Welfare, Punjab
• Treatments: Antiviral Agents; Ledipasvir; Sofosbuvir

Criteria

Inclusion Criteria:

• Chronic Hepatitis C

• Age: >18 years

Exclusion Criteria:

• Chronic liver disease of a non-HCV etiology

• Serum Creatinine >1.5 mg/dl

• Evidence of hepatocellular carcinoma or other malignancy

• Significant cardiovascular, pulmonary, or neurological disease

• History of solid organ or bone marrow transplantation.